| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SMTI | Common Stock | Award | $0 | +10.8K | +23.66% | $0.00 | 56.5K | Jun 12, 2024 | Direct | F1 |
| holding | SMTI | Common Stock | 2.45M | Jun 12, 2024 | See Footnote | F2 | |||||
| holding | SMTI | Common Stock | 964K | Jun 12, 2024 | See Footnote | F3 |
| Id | Content |
|---|---|
| F1 | Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Company") to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated. The shares of restricted stock will vest on June 12, 2025, provided that the reporting person is providing certain services to the Company through such date. |
| F2 | Represents shares of the Company's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein. |
| F3 | Represents shares of the Company's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein. |